
Lumos Pharma Inc
NASDAQ:LUMO

Intrinsic Value
The intrinsic value of one
LUMO
stock under the Base Case scenario is
16.83
USD.
Compared to the current market price of 4.34 USD,
Lumos Pharma Inc
is
Undervalued by 74%.
The Intrinsic Value is calculated as the average of DCF and Relative values:

Valuation History
Lumos Pharma Inc
Fundamental Analysis


Revenue & Expenses Breakdown
Lumos Pharma Inc
Balance Sheet Decomposition
Lumos Pharma Inc
Current Assets | 17.3m |
Cash & Short-Term Investments | 13.5m |
Receivables | 174k |
Other Current Assets | 3.6m |
Non-Current Assets | 187k |
PP&E | 187k |
Free Cash Flow Analysis
Lumos Pharma Inc
USD | |
Free Cash Flow | USD |
Earnings Waterfall
Lumos Pharma Inc
Revenue
|
2.2m
USD
|
Operating Expenses
|
-38.5m
USD
|
Operating Income
|
-36.3m
USD
|
Other Expenses
|
1.4m
USD
|
Net Income
|
-34.9m
USD
|
LUMO Profitability Score
Profitability Due Diligence
Lumos Pharma Inc's profitability score is 20/100. The higher the profitability score, the more profitable the company is.

Score
Lumos Pharma Inc's profitability score is 20/100. The higher the profitability score, the more profitable the company is.
LUMO Solvency Score
Solvency Due Diligence
Lumos Pharma Inc's solvency score is 51/100. The higher the solvency score, the more solvent the company is.

Score
Lumos Pharma Inc's solvency score is 51/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
LUMO Price Targets Summary
Lumos Pharma Inc
Dividends
Current shareholder yield for LUMO is
.
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
The intrinsic value of one
LUMO
stock under the Base Case scenario is
16.83
USD.
Compared to the current market price of 4.34 USD,
Lumos Pharma Inc
is
Undervalued by 74%.